Oblita Therapeutics

Foundation date

08/03/2016

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

Oblita Therapeutics is a global health research & development start-up company. Our goal is to close current therapeutic gaps and improve the quality of life of those suffering from “forgotten” (neglected) diseases. Oblita Therapeutics’ lead program is focused on the development of a new drug (D121) to treat leishmaniasis (starting phase II). We have convincing preclinical results on the effectiveness of D121 against Cryptosporidium Parvum infection, Chagas Disease, and Fungal Infections.

Upcoming events

Latest news

  • reMYND announces positive Phase 2a clinical trial results for treatment of mild-to-moderate Alzheimer’s disease

    20 hours ago

  • Can we protect nerve cells from dying?

    20 hours ago

  • Resistance in Candida auris, how to tackle a deadly fungus

    Wednesday October 30th 2024